Denali Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.13M Sell
6,987
-38
-0.5% -$6.33K 0.11% 181
2026
Q2
$1.33M Sell
7,025
-294
-4% -$55.3K 0.13% 164
2026
Q1
$1.44M Buy
7,319
+319
+5% +$61.5K 0.16% 145
2025
Q4
$1.29M Buy
7,000
+2,512
+56% +$441K 0.14% 151
2025
Q3
$689K Sell
4,488
-2,501
-36% -$379K 0.08% 205
2025
Q2
$977K Sell
6,989
-44
-0.6% -$6.17K 0.1% 176
2025
Q1
$1.03M Buy
7,033
+1,239
+21% +$179K 0.12% 167
2024
Q4
$759K Sell
5,794
-1,236
-18% -$173K 0.08% 196
2024
Q3
$1.1M Buy
+7,030
New +$1.13M 0.12% 164

Other funds holding AZN

Denali Advisors's AZN Position: Q3 2026 in Review

Denali Advisors reduced its AstraZeneca (AZN) stake by 0.54% in Q3 2026, selling an estimated $6.33K and leaving 6,987 shares worth $1.13M. The position accounts for 0.11% of the portfolio, ranked #181.

Denali Advisors first reported a position in AZN in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.44M in Q1 2026. 1,429 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Denali Advisors held 6,987 shares of AstraZeneca worth $1.13M as of Q3 2026.
  • Denali Advisors sold 38 AstraZeneca shares in Q3 2026, an estimated $6.33K.
  • AstraZeneca made up 0.11% of Denali Advisors's portfolio in Q3 2026, its #181 holding.
  • Denali Advisors first reported a position in AstraZeneca in Q3 2024 and has held it in 9 quarters since.
  • Denali Advisors's AstraZeneca position peaked at $1.44M in Q1 2026.
  • 1,429 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Denali Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.